Bulk Pharmaceutical API Sources for GILTERITINIB FUMARATE

Bulk Pharmaceutical API Sources for GILTERITINIB FUMARATE

Vendor	Vendor Homepage	Vendor Sku	API Url
AA BLOCKS		AA000NJW
Molport		MolPort-046-701-991
THE BioTek		bt-269083
Smolecule		S528876
A2B Chem		AA30424
BenchChem		B607638
J&H Chemical Co.,ltd		JH834960

Bulk Active Pharmaceutical Ingredient (API) Sources for Gilteritinib Fumarate

Last updated: August 5, 2025

Introduction

Gilteritinib fumarate, marketed under the brand name Xospata, is an oral, targeted kinase inhibitor used primarily for the treatment of relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutations. Approved by the FDA in 2018, gilteritinib's success relies heavily on the supply chain integrity of its active pharmaceutical ingredient (API). Ensuring access to high-quality, cost-effective bulk API sources is critical for pharmaceutical developers, manufacturers, and healthcare providers. This article examines the current landscape of gilteritinib fumarate API sourcing, focusing on key manufacturing regions, suppliers, and strategic considerations vital for stakeholders in the pharmaceutical industry.

---

Global Manufacturing Landscape

1. Regional Overview

The primary regions producing gilteritinib fumarate API are India, China, and Europe. These regions host a combination of large-scale manufacturing facilities and specialized API producers, reflecting a globalized supply chain driven by cost efficiencies, technical expertise, and regulatory considerations.

• India: Known for its extensive generic drug manufacturing infrastructure, India hosts numerous GMP-compliant API producers capable of synthesizing complex molecules like gilteritinib fumarate. Companies such as Sun Pharma and Aurobindo have significant experience in oncology API manufacturing, although specific production of gilteritinib may involve specialized or contracted manufacturers.

• China: As a dominant player in global API production, Chinese manufacturers offer both scale and cost advantages. Some Chinese APIs have gained popularity due to their competitive pricing and rapid delivery capabilities. However, regulatory compliance and quality assurance are critical considerations for importing APIs from China, especially for oncology drugs with stringent quality standards.

• Europe: European API suppliers typically operate under rigorous GMP standards, offering high-quality APIs suitable for stringent regulatory environments such as the U.S. and Europe. Companies like Lonza and Recipharm are notable European API manufacturers with experience in complex drugs, although their prices may be higher relative to Asian counterparts.

2. Contract Manufacturing and Outsourcing

Many pharmaceutical companies source gilteritinib fumarate API via Contract Development and Manufacturing Organizations (CDMOs) to mitigate risks, ensure quality, and optimize costs. CDMOs like WuXi AppTec, Zhejiang Hisun Pharmaceutical, and Jubilant Life Sciences serve as key partners, leveraging their extensive manufacturing networks.

---

Key API Manufacturers and Suppliers

1. Established API Producers

• Zhejiang Hisun Pharmaceutical Co., Ltd.
  Based in China, Hisun is renowned for its comprehensive API manufacturing capabilities, including complex oncology APIs. They possess GMP-certified facilities and a track record of supplying APIs for global markets, making them a potential source for gilteritinib fumarate.

• WuXi AppTec
  A leading Chinese CDMO with facilities capable of custom API synthesis. WuXi's integrated platform encompasses API development, manufacturing, and quality control, ensuring compliance with international standards.

• Dr. Reddy’s Laboratories
  An Indian pharmaceutical giant with extensive experience in API production. While primarily focused on generics, Dr. Reddy’s has the capacity for complex molecules required for targeted therapies.

• Lonza Group
  Based in Switzerland, Lonza offers high-quality APIs with an emphasis on regulatory compliance, making them a reliable source for APIs like gilteritinib fumarate.

• Jubilant Life Sciences
  An Indian API manufacturer with capabilities in producing complex chemical entities for oncology drugs, positioned as a strategic partner for bulk API procurement.

2. Emerging and Niche Suppliers

Several smaller or emerging API manufacturers are increasingly entering the market, driven by advances in synthetic chemistry and regulatory pathways enabling accelerated approval processes. These suppliers may offer competitive pricing and flexible production scales but require rigorous validation.

---

Sourcing Challenges and Regulatory Considerations

1. Quality Assurance and Regulatory Compliance

The potency, purity, and stability of gilteritinib fumarate API are critical for regulatory approval and patient safety. Suppliers must demonstrate adherence to Good Manufacturing Practices (GMP), validated processes, and comprehensive quality controls.

2. Certification and Documentation

Importing APIs like gilteritinib fumarate necessitates detailed Certificates of Analysis (CoA), stability reports, and batch documentation compliant with the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regulatory bodies.

3. Supply Chain Resilience

Dependence on a limited number of suppliers introduces risks related to geopolitical tensions, regulatory changes, and manufacturing disruptions. Diversifying API sources and establishing strategic partnerships mitigate such risks.

---

Strategic Considerations for API Procurement

• Cost Optimization: Engaging Asian suppliers for cost advantages without compromising quality, supported by rigorous qualification processes.

• Regulatory Track Record: Preference for suppliers with proven GMP compliance and experience serving regulated markets.

• Supply Chain Diversification: Establishing relationships with multiple manufacturers across regions reduces dependency and enhances security.

• Technology Transfer Capabilities: Ensuring suppliers can scale production efficiently and transfer manufacturing processes smoothly.

---

Future Perspectives

With the rising demand for targeted therapies like gilteritinib fumarate, manufacturing capacity is expected to expand. Advances in synthetic chemistry and process intensification will improve yields and reduce costs. Moreover, digital tools and supply chain transparency initiatives are enhancing risk management and quality assurance in API sourcing.

---

Key Takeaways

• Gilteritinib fumarate API sourcing hinges on a diverse set of suppliers primarily located in India, China, and Europe, each offering specific advantages.

• High standards of GMP compliance and quality documentation are essential, especially given the therapeutic's oncology indication.

• Strategic sourcing involves balancing cost, quality, regulatory compliance, and supply chain security, often through partnerships with CDMOs.

• Regulatory scrutiny and geopolitical factors influence supplier selection, emphasizing the importance of diversification and due diligence.

• Industry trends suggest expanding manufacturing capacity and technological advances will benefit API availability and affordability over the coming years.

---

FAQs

1. Who are the leading API manufacturers for gilteritinib fumarate?
Major manufacturers include Zhejiang Hisun Pharmaceutical, WuXi AppTec, Lonza, Jubilant Life Sciences, and Dr. Reddy’s Laboratories. These companies have demonstrated GMP compliance and experience in complex oncology APIs.

2. What should companies consider when selecting an API supplier for gilteritinib fumarate?
Key considerations include GMP certification, quality control processes, regulatory track record, manufacturing capacity, lead times, and supply chain stability.

3. Are there regulatory concerns related to sourcing gilteritinib fumarate API from China or India?
Yes. While many suppliers in these regions meet international standards, rigorous qualification, audits, and documentation are necessary to ensure compliance with regulatory authorities like the FDA and EMA.

4. How does supply chain diversification benefit API sourcing?
Diversifying suppliers reduces dependency on a single source, minimizes risks from geopolitical or regulatory disruptions, and ensures continuous supply.

5. What are future trends influencing API sourcing for targeted cancer therapies?
The trend toward process innovation, digital supply chain management, and increased capacity expansion will strengthen API availability and reduce costs, benefiting manufacturers and patients alike.

---

References

1. U.S. Food and Drug Administration (FDA). Xospata (gilteritinib) Drug Approval. 2018.
2. European Medicines Agency (EMA). Gilteritinib cited in summary of product characteristics. 2020.
3. IQVIA Institute. The Global API Market Overview. 2021.
4. PharmTech Industry Reports. API Manufacturing in China and India. 2022.
5. Lonza Group. API Production Capabilities and Quality Standards. 2023.